CG Oncology, Inc.
CGON
$75.03
$0.320.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 6.83% | -53.36% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.83% | -53.36% | |||
| Cost of Revenue | 25.46% | 41.37% | |||
| Gross Profit | -25.91% | -48.53% | |||
| SG&A Expenses | 39.44% | 15.48% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.77% | 32.24% | |||
| Operating Income | -30.14% | -36.32% | |||
| Income Before Tax | -31.32% | -45.74% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -31.32% | -45.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -31.32% | -45.74% | |||
| EBIT | -30.14% | -36.32% | |||
| EBITDA | -30.52% | -36.98% | |||
| EPS Basic | -25.83% | -38.04% | |||
| Normalized Basic EPS | -25.83% | -38.05% | |||
| EPS Diluted | -25.83% | -38.04% | |||
| Normalized Diluted EPS | -25.83% | -38.05% | |||
| Average Basic Shares Outstanding | 4.36% | 5.56% | |||
| Average Diluted Shares Outstanding | 4.36% | 5.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||